Open Questions: Entities

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
61 questions found for field 'Entities'
open ⚖ 1500
Microfluidic platforms
📑 0.50 💥 0.50
open ⚖ 1500
3D culture systems
📑 0.50 💥 0.50
open ⚖ 1500
CRISPR screening
📑 0.50 💥 0.50
open ⚖ 1500
iPSC comparison
📑 0.50 💥 0.50
open ⚖ 1500
Subcutaneous formulation:
📑 0.50 💥 0.50
open ⚖ 1500
Fixed-dose regimen:
📑 0.50 💥 0.50
open ⚖ 1500
Biannual dosing:
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-driven selection
📑 0.50 💥 0.50
open ⚖ 1500
Genetic stratification
📑 0.50 💥 0.50
open ⚖ 1500
Disease stage optimization
📑 0.50 💥 0.50
open ⚖ 1500
Multiple antibodies
📑 0.50 💥 0.50
open ⚖ 1500
Small molecules
📑 0.50 💥 0.50
open ⚖ 1500
Cell replacement
📑 0.50 💥 0.50
open ⚖ 1500
Symptomatic drugs
📑 0.50 💥 0.50
open ⚖ 1500
Clinical endpoints
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker endpoints
📑 0.50 💥 0.50
open ⚖ 1500
Digital biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Composite endpoints
📑 0.50 💥 0.50
open ⚖ 1500
Cell type-specific functions
📑 0.50 💥 0.50
open ⚖ 1500
Post-translational modifications
📑 0.50 💥 0.50
open ⚖ 1500
Interorganellar communication
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker potential
📑 0.50 💥 0.50
open ⚖ 1500
Engineered Fc:
📑 0.50 💥 0.50
open ⚖ 1500
Bispecific antibodies:
📑 0.50 💥 0.50
open ⚖ 1500
Smaller formats:
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy:
📑 0.50 💥 0.50
open ⚖ 1500
Which patient subgroups show tractable TrkB pathway insufficiency signatures?
📑 0.50 💥 0.50
open ⚖ 1500
What target engagement threshold predicts durable synaptic rescue?
📑 0.50 💥 0.50
open ⚖ 1500
How should TrkB therapies be sequenced with disease-specific upstream interventions?
📑 0.50 💥 0.50
open ⚖ 1500
Which biomarkers best capture pathway activation in vivo?
📑 0.50 💥 0.50
open ⚖ 1500
Can chronic pathway activation remain safe in older multimorbid populations?
📑 0.50 💥 0.50
open ⚖ 1500
Cell type-specific functions**: How does BNIP1 function differ between neurons, astrocytes, and microglia?
📑 0.50 💥 0.50
open ⚖ 1500
Post-translational modifications**: How do phosphorylation, ubiquitination, and other modifications affect BNIP1 activity?
📑 0.50 💥 0.50
open ⚖ 1500
Interorganellar communication**: How does BNIP1 coordinate ER-mitochondria contacts under different stress conditions?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window**: Can BNIP1 be safely modulated without disrupting normal cellular function?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker potential**: Can BNIP1 expression or variants serve as biomarkers for neurodegenerative disease?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of pathogenesis**: How do specific mutations lead to neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Normal function**: What is the physiological role of LRRK2 in neurons?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers**: Can we develop LRRK2-specific biomarkers for clinical use?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows**: What is the optimal level of LRRK2 inhibition for benefit?
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies**: What other targets should be combined with LRRK2 inhibition?
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection**: Which patients are most likely to benefit from LRRK2-targeted therapies?
📑 0.50 💥 0.50
open ⚖ 1500
Peripheral vs. central histamine
📑 0.50 💥 0.50
open ⚖ 1500
Translation of preclinical findings
📑 0.50 💥 0.50
open ⚖ 1500
Receptor subtype-specific effects
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics
📑 0.50 💥 0.50
open ⚖ 1500
CRISPR screening
📑 0.50 💥 0.50
open ⚖ 1500
3D culture systems
📑 0.50 💥 0.50
open ⚖ 1500
Co-culture systems
📑 0.50 💥 0.50
open ⚖ 1500
Microfluidic devices
📑 0.50 💥 0.50
open ⚖ 1500
Patient-derived models
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of pathogenesis
📑 0.50 💥 0.50
open ⚖ 1500
Normal function
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic Regulators
📑 0.50 💥 0.50
open ⚖ 1500
Non-Coding RNAs
📑 0.50 💥 0.50
open ⚖ 1500
Metabolomic Entities
📑 0.50 💥 0.50
open ⚖ 1500
Single-Cell Markers
📑 0.50 💥 0.50
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map